Skip to main content
Profile picture for Ian Bruce, MD, FRCP

Ian Bruce, MD, FRCP

Ian Bruce is a National Institute of Health Research Senior Investigator and Professor of Rheumatology at the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, University of Manchester. He is Director of The NIHR Manchester Biomedical Research Centre. Professor Bruce is immediate past Chair of the Systemic Lupus International Collaborating Clinics (SLICC), a member of the British Isles Lupus Assessment Group and leads the BILAG Biologics Register. He is also Chief Investigator in the MASTERPLANS Consortium, an MRC-funded Stratified Medicine Consortium. He participates in a number of national and international multicentre studies that are seeking to refine our understanding of SLE and serves on Data Safety Steering Committees in several commercial and academic clinical trials. Professor Bruce’s research is focused on the association between inflammatory rheumatic diseases and premature atherosclerosis/coronary heart disease as well as stratified medicine in SLE.

Articles By Ian Bruce, MD, FRCP

pregnant_0.jpg

Pregnancy and Contraception in Patients with Rheumatic Diseases

A number of abstracts at this year’s ACR in Chicago highlighted issues around pregnancy and contraception advice in routine clinical practice.

Read Article
moneyglobe.jpg

Health Economics of SLE

A number of presentations over the past few days have addressed the health economics of SLE.

Read Article
lupus.bandtest.jpg

Two Lupus Studies

In this session we were given new data on ustekinumab for SLE (

Read Article
clinical-trial-icon-2793430_640.png

SLE Clinical Trial Design and Outcome Measures

Clinical trials remain a challenge in SLE and a number of outcome measures have been used with varying success.Two abstracts in this session sought to address novel ways to assess responses in SLE trials.

Read Article
heart.jpg (keep)

RA and Cardiac Co-Morbidities

We know that cardiovascular disease (CVD) is the leading cause of death in RA and that traditional risk factors do not fully account for increased risk.

Read Article
×